Merck CEO Frazier to testify at Senate drug pricing hearing
Republican Senator Chuck Grassley, chairman of the Senate Finance Committee, and Democratic Senator Ron Wyden, ranking member of the committee, on Monday, invited executives from seven pharmaceutical companies, including Merck, to testify.
NEW YORK: U.S. drug company Merck & Co Inc said on Tuesday that its Chief Executive Ken Frazier plans to testify at a Senate hearing later this month examining rising prescription drug prices.
Republican Senator Chuck Grassley, chairman of the Senate Finance Committee, and Democratic Senator Ron Wyden, ranking member of the committee, on Monday, invited executives from seven pharmaceutical companies, including Merck, to testify.
Read Also: Merck strengthens animal health unit with $2.4 billion Antelliq purchase
The other companies are AbbVie Inc, AstraZeneca PLC, Bristol-Myers Squibb Co, Johnson & Johnson, Pfizer Inc and Sanofi SA.
A spokesman from Senator Grassley's office said on Monday that two of the CEOs have agreed to testify so far, but did not say what companies they were from.
Read Also: Merck KEYTRUDA receives five new approvals in Japan
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd